/Huang Lei

(黃磊，Dept Hepatobil Surg，Peking Univ Peop Hosp，Beijing 100044)…∥Chin J Gen Surg.-2011，26(11).-936 ～939

ObjectiveTo observe the efficacy of Sorafenib in preventing and treating tumor recurrence after liver transplantation for patients with primary hepatic carcinoma beyond Milan criteria.MethodsFrom March 2008 to June 2010，30 patients of liver transplantation with primary hepatic carcinoma exceeding Milan criteria were randomized into 2 groups，each group of 15 cases.Beginning one month posttransplantatoin patients in the experimental group received oral administration of Sorafenib(400 mg bid)，while those in the control group received Capecitabine(1500 mg bid)for 14 days every 4 weeks.Drug was withdrawn in patients without recurrence in 18 months after transplantation，recurrent patients maintained the original dose until they were not suitable for the medication.ResultsThe 1 year recurrence rate in experimental group was 53.3%，that in control group was 86.6%(x2=3.968，P ＜0.05).The 1 year survival rate in experimental group was 93.3%，that in the control group was 46.6%(x2=7.777，P ＜0.05).The mean survival time of patients in experimental group was(24.6 ±1.7)months(7-28 months)，that in the control group was(16.4 ±2.7)months(5-34 months)(x2=7.154，P ＜0.05).Most adverse reactions in both groups were of grade Ⅰ-Ⅱ.The incidence of diarrhea and handfoot syndrome in experimental group is higher than that in control group.ConclusionUsing Sorafenib for patients with primary hepatic carcinoma exceeding Milan criteria after liver transplantation may reduce carcinoma recurrence rate，and prolong patients’survival time.11 refs，1 figs，2 tabs